Envestnet Asset Management Inc. Has $4.74 Million Holdings in Express Scripts (ESRX)

Envestnet Asset Management Inc. trimmed its holdings in shares of Express Scripts (NASDAQ:ESRX) by 61.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 68,464 shares of the company’s stock after selling 111,122 shares during the period. Envestnet Asset Management Inc.’s holdings in Express Scripts were worth $4,740,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. James Investment Research Inc. boosted its holdings in shares of Express Scripts by 2.2% during the fourth quarter. James Investment Research Inc. now owns 30,241 shares of the company’s stock worth $2,257,000 after purchasing an additional 656 shares during the period. Dowling & Yahnke LLC boosted its holdings in shares of Express Scripts by 3.0% during the first quarter. Dowling & Yahnke LLC now owns 24,496 shares of the company’s stock worth $1,692,000 after purchasing an additional 722 shares during the period. First National Bank of Omaha boosted its holdings in shares of Express Scripts by 7.4% during the fourth quarter. First National Bank of Omaha now owns 11,060 shares of the company’s stock worth $825,000 after purchasing an additional 765 shares during the period. Palladium Partners LLC boosted its holdings in shares of Express Scripts by 4.1% during the fourth quarter. Palladium Partners LLC now owns 19,666 shares of the company’s stock worth $1,468,000 after purchasing an additional 772 shares during the period. Finally, Twin Capital Management Inc. boosted its holdings in shares of Express Scripts by 0.9% during the first quarter. Twin Capital Management Inc. now owns 103,340 shares of the company’s stock worth $7,139,000 after purchasing an additional 880 shares during the period. Institutional investors and hedge funds own 85.82% of the company’s stock.

In other Express Scripts news, VP Everett Neville sold 4,895 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $75.26, for a total transaction of $368,397.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Christine Houston sold 19,889 shares of the firm’s stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $76.69, for a total transaction of $1,525,287.41. The disclosure for this sale can be found here. 0.79% of the stock is currently owned by company insiders.

ESRX has been the subject of several research analyst reports. ValuEngine lowered shares of Express Scripts from a “buy” rating to a “hold” rating in a report on Wednesday, May 2nd. Barclays initiated coverage on shares of Express Scripts in a report on Thursday, March 8th. They issued an “equal weight” rating and a $84.00 price objective for the company. Maxim Group lowered shares of Express Scripts from a “buy” rating to a “hold” rating in a report on Thursday, March 8th. Zacks Investment Research lowered shares of Express Scripts from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 13th. Finally, Wells Fargo & Co upgraded shares of Express Scripts from an “underperform” rating to a “market perform” rating in a report on Friday, March 9th. Four analysts have rated the stock with a sell rating, twelve have given a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $82.50.

Shares of NASDAQ ESRX opened at $76.80 on Friday. Express Scripts has a fifty-two week low of $55.80 and a fifty-two week high of $85.07. The company has a market cap of $43.26 billion, a price-to-earnings ratio of 10.82, a price-to-earnings-growth ratio of 0.97 and a beta of 0.98. The company has a quick ratio of 0.56, a current ratio of 0.69 and a debt-to-equity ratio of 0.81.

Express Scripts (NASDAQ:ESRX) last announced its earnings results on Wednesday, May 2nd. The company reported $1.77 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.76 by $0.01. Express Scripts had a net margin of 4.59% and a return on equity of 25.41%. The business had revenue of $24.77 billion during the quarter, compared to the consensus estimate of $24.80 billion. During the same quarter last year, the firm earned $1.33 earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. sell-side analysts anticipate that Express Scripts will post 9.07 EPS for the current year.

Express Scripts Company Profile

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.

Want to see what other hedge funds are holding ESRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Express Scripts (NASDAQ:ESRX).

Institutional Ownership by Quarter for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply